CNBC · Finance · 2026-08-19
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone. Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
Read original on CNBC Get the app
Licensed summary · LicensedSummary
Related briefs
- Mint Explainer | Why Sebi wants to revamp its settlement framework
- Stocks making the biggest moves premarket: Moderna, Lowe's, Estee Lauder & more
- U.S. retreat from global order ‘eroding’ European competitiveness, central bank boss warns
- Retail investors aren't entirely giving up on AI trade, but they appear more cautious
- Weekly mortgage demand stalls along with interest rates, but rates are now moving higher again.